ES2871551T3 - Bloqueadores del receptor de la hormona del crecimiento en la prevención y el tratamiento de enfermedades - Google Patents

Bloqueadores del receptor de la hormona del crecimiento en la prevención y el tratamiento de enfermedades Download PDF

Info

Publication number
ES2871551T3
ES2871551T3 ES16749947T ES16749947T ES2871551T3 ES 2871551 T3 ES2871551 T3 ES 2871551T3 ES 16749947 T ES16749947 T ES 16749947T ES 16749947 T ES16749947 T ES 16749947T ES 2871551 T3 ES2871551 T3 ES 2871551T3
Authority
ES
Spain
Prior art keywords
ghr
igf
growth hormone
mice
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16749947T
Other languages
English (en)
Spanish (es)
Inventor
Valter D Longo
Priya Balasubramanian
Nouri Neamati
Min Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Application granted granted Critical
Publication of ES2871551T3 publication Critical patent/ES2871551T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
ES16749947T 2015-02-12 2016-02-12 Bloqueadores del receptor de la hormona del crecimiento en la prevención y el tratamiento de enfermedades Active ES2871551T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115356P 2015-02-12 2015-02-12
PCT/US2016/017717 WO2016130901A2 (en) 2015-02-12 2016-02-12 Blockers of the growth hormone receptor in disease prevention and treatment

Publications (1)

Publication Number Publication Date
ES2871551T3 true ES2871551T3 (es) 2021-10-29

Family

ID=56615057

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16749947T Active ES2871551T3 (es) 2015-02-12 2016-02-12 Bloqueadores del receptor de la hormona del crecimiento en la prevención y el tratamiento de enfermedades

Country Status (14)

Country Link
US (2) US10246446B2 (enExample)
EP (1) EP3256465B1 (enExample)
JP (2) JP6930916B2 (enExample)
KR (1) KR20180016333A (enExample)
CN (1) CN107438605B (enExample)
AU (1) AU2016219173B2 (enExample)
BR (1) BR112017017182A2 (enExample)
CA (1) CA2976219C (enExample)
ES (1) ES2871551T3 (enExample)
IL (1) IL253943A0 (enExample)
MX (1) MX383010B (enExample)
NZ (1) NZ734252A (enExample)
RU (1) RU2726254C2 (enExample)
WO (1) WO2016130901A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
CN120865406A (zh) * 2024-04-30 2025-10-31 长春金赛药业有限责任公司 Ghr激动型抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701010D0 (sv) * 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
US20040204368A1 (en) 2001-05-31 2004-10-14 Kazuyuki Ohmoto Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
WO2006001770A1 (en) * 2004-06-28 2006-01-05 Biovitrum Ab Method for identifying modulators of cytokine class i receptor
RU2415134C9 (ru) * 2005-08-15 2011-05-27 Этерна Центарис ГмбХ Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2011013039A1 (en) * 2009-07-28 2011-02-03 Koninklijke Philips Electronics N.V. Housing with locking structure
RU2014123030A (ru) * 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013123511A1 (en) * 2012-02-16 2013-08-22 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
US9732067B2 (en) * 2012-06-20 2017-08-15 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
CA2900782C (en) 2013-02-12 2022-09-27 University Of Southern California Methods and diets to protect against chemotoxicity and age related illnesses

Also Published As

Publication number Publication date
RU2017129335A3 (enExample) 2019-08-07
US10246446B2 (en) 2019-04-02
MX2017010306A (es) 2018-03-15
MX383010B (es) 2025-03-13
CA2976219A1 (en) 2016-08-18
CN107438605A (zh) 2017-12-05
IL253943A0 (en) 2017-10-31
WO2016130901A2 (en) 2016-08-18
EP3256465A4 (en) 2018-10-31
CA2976219C (en) 2021-05-04
EP3256465A2 (en) 2017-12-20
EP3256465B1 (en) 2021-04-07
RU2017129335A (ru) 2019-03-12
AU2016219173B2 (en) 2020-02-20
WO2016130901A3 (en) 2016-10-20
NZ734252A (en) 2020-06-26
AU2016219173A1 (en) 2017-08-17
BR112017017182A2 (pt) 2018-04-03
RU2726254C2 (ru) 2020-07-10
JP6930916B2 (ja) 2021-09-01
US20170342063A1 (en) 2017-11-30
KR20180016333A (ko) 2018-02-14
JP2018506534A (ja) 2018-03-08
JP2021075553A (ja) 2021-05-20
CN107438605B (zh) 2021-03-19
US20190276445A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
ES2270586T3 (es) Compuestos y metodos para el tratamiento de tumores.
Harhaj et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability
Liu et al. p38β MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice
Sridaran et al. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
El-Merahbi et al. The adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
US20150361146A1 (en) MG53 Mutant, Methods of Mutation and Use Thereof
ES2958662T3 (es) Tratamiento de cardiopatía por inhibición de la acción de la proteína de anclaje a la cinasa A del músculo (mAKAP)
JP2021075553A (ja) 疾患予防および治療における成長ホルモン受容体の遮断剤
Fu et al. β-arrestin-2 enhances intestinal epithelial apoptosis in necrotizing enterocolitis
WO2016176617A2 (en) Method for treating high-grade gliomas
WO2023053142A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
ES2868354T3 (es) Péptido Naktide para el tratamiento de la obesidad
Zhang et al. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling
US20100330098A1 (en) Methods to regulate glucose metabolism
Nandi Cellular and metabolic reprogramming in breast Cancer and its therapeutic implications
Smithberger Kinome-Guided Development of Precision-Targeted Therapeutics for Glioblastoma
WO2024188321A1 (zh) Ofd1蛋白或基因作为靶点在肿瘤预防与治疗中的应用
HK40071673B (en) Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
Oakie The role of c-Kit and insulin receptor tyrosine kinases in beta cell function and insulin secretion
Chung et al. Microenvironmental adaptations drive obesity-associated pancreatic cancer
WO2015073813A2 (en) Compositions and methods for the treatment of diseases involving hippo pathway
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
Neumann The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes